Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape
Authors:
- Meghana N. PatelMeghana N. Patel
- Archita J. PatelArchita J. Patel
- Manish N. NandpalManish N. Nandpal
- Manan A. RavalManan A. Raval
- Ravish J. PatelRavish J. Patel
- Amit A. PatelAmit A. Patel
- Keshav Raj PaudelKeshav Raj Paudel
- Philip M. HansbroPhilip M. Hansbro
- Sachin Kumar SinghSachin Kumar Singh
- Gaurav GuptaGaurav Gupta
- Kamal DuaKamal Dua
- Samir G. PatelSamir G. Patel
- 8 October 2024
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (3) , 2127-2150
Abstract
Drug-resistant tuberculosis (DR-TB) represents a pressing global health issue, leading to heightened morbidity and mortality. Despite extensive research efforts, the escalation of DR-TB cases underscores the urgent need for enhanced prevention, diagnosis, and treatment strategies. This review delves deep into the molecular and genetic origins of different types of DR-TB, highlighting recent breakthroughs in detection and diagnosis, including Rapid Diagnostic Tests like Xpert Ultra, Whole Genome Sequencing, and AI-based tools along with latest viewpoints on diagnosis and treatment of DR-TB utilizing newer and repurposed drug molecules. Special emphasis is given to the pivotal role of novel drugs and discusses updated treatment regimens endorsed by governing bodies, alongside innovative personalized drug-delivery systems such as nano-carriers, along with an analysis of relevant patents in this area. All the compiled information highlights the inherent challenges of current DR-TB treatments, discussing their complexity, potential side effects, and the socioeconomic strain they impose, particularly in under-resourced regions, emphasizing the cost-effective and accessible solutions. By offering insights, this review aims to serve as a compass for researchers, healthcare practitioners, and policymakers, emphasizing the critical need for ongoing R&D to improve treatments and broaden access to crucial TB interventions. Graphical Abstract - The escalating burden of DR-TB represents a significant global health threat. - Effective strategies are needed for DR-TB's prevention, diagnosis, and treatment. - The review emphasizes DR-TB management with novel techniques and AI approaches. - It also focuses on relevant patents related to DR-TB management. - It underscores continuous research for effective DR-TB control challenges.Keywords
This publication has 165 references indexed in Scilit:
- Characterization of mutations in streptomycin-resistant Mycobacterium tuberculosis clinical isolates in the area of BarcelonaJournal of Antimicrobial Chemotherapy, 2010
- Drug‐resistant tuberculosis: Past, present, futureRespirology, 2010
- Multidrug resistant to extensively drug resistant tuberculosis: What is next?Journal of Biosciences, 2008
- Recent advances in multi-drug-resistant tuberculosis and RNTCPIndian Journal of Community Medicine, 2008
- Novel Gyrase Mutations in Quinolone-Resistant and -Hypersusceptible Clinical Isolates of Mycobacterium tuberculosis : Functional Analysis of Mutant EnzymesAntimicrobial Agents and Chemotherapy, 2006
- Mutation of tlyA Confers Capreomycin Resistance in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2005
- Novel Mutations within the embB Gene in Ethambutol-Susceptible Clinical Isolates of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2004
- Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in PeruThe Lancet, 2002
- Efflux-Mediated Resistance to Fluoroquinolones in Gram-Negative BacteriaAntimicrobial Agents and Chemotherapy, 2000
- Standard Short-Course Chemotherapy for Drug-Resistant TuberculosisJAMA, 2000